Role of p38 inhibition in cardiac ischemia/reperfusion injury

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 513-524

  Kumphune, Sarawut ^a,b   Chattipakorn, Siriporn ^b,c   Chattipakorn, Nipon ^b,d  

^a NARESUAN UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Myocardial ischemia reperfusion; P38 Inhibitors; P38 Mitogen activated protein kinase; Therapy

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; CASPASE 3; CREATINE KINASE; CYTOCHROME C; DORAMAPIMOD; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SB 242719; SC 409; UNCLASSIFIED DRUG;

APOPTOSIS; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; EX VIVO STUDY; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOTONIC AGENTS; ENZYME ACTIVATION; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS;

EID: 84864278617     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1193-2     Document Type: Review

References (87)

1. World Health Organization (2008) World Heath Statistics 2008. World Health Organization, Geneva
2. Jennings RB, Reimer KA (1991) The cell biology of acute myocardial ischemia. Annu Rev Med 42:225-246. doi:10.1146/annurev.me.42.020191.001301
3. Braunwald E (1998) Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 352(9142):1771-1774. doi:10.1016/s0140-6736(98)03212-7 (Pubitemid 28534971)
4. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94(4):1621-1628. doi:10.1172/JCI117504 (Pubitemid 24309885)
5. Schulz R (2005) A new paradigm: cross talk of protein kinases during reperfusion saves life! Am J Physiol Heart Circ Physiol 288 (1):H1-H2. doi:10.1152/ajpheart.00886.2004 (Pubitemid 40023819)
6. Clark JE, Sarafraz N, Marber MS (2007) Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Therapeutics 116(2):192-206 (Pubitemid 47451511)
7. U.S. National Institutes of Health (2011) A study to evaluate the effects of 3 months dosing with GW856553, as assessed FDG-PET/CT imaging. Available at: http://clinicaltrials.gov/ct2/show/study/NCT00633022. Accessed 26 Sept 2011
8. U.S. National Institutes of Health (2011) Efficacy study of p38 kinase inhibitor to treat patients with atherosclerosis. Available at: http://clinicaltrials.gov/ct2/show/NCT00570752?term0NCT00570752&rank01. Accessed 26 Sept 2011
9. U.S. National Institutes of Health (2011) A pharmacokinetic study of SB-681323 in subjects with coronary heart disease undergoing percutaneous intervention. Available at: http://clinicaltrials.gov/ct2/show/NCT00291902? term0SB-681323&rank09. Accessed 26 Sept 2011
10. Sarov-Blat L, Morgan JM, Fernandez P, James R, Fang Z, Hurle MR, Baidoo C, Willette RN, Lepore JJ, Jensen SE, Sprecher DL (2010) Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans. Arterioscler Thromb Vac Biol 30(11):2256-2263. doi:10.1161/atvbaha.110.209205
11. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Land Vatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372(6508):739-746
12. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, Nebreda AR (1994) A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78(6):1027-1037. doi:10.1016/0092-8674(94)90277-1 (Pubitemid 24292330)
13. Han J, Lee JD, Bibbs L, Ulevitch RJ (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265(5173):808-811 (Pubitemid 24266145)
14. Han J, Richter B, Li Z, Kravchenko VV, Ulevitch RJ (1995) Molecular cloning of human p38 MAP kinase. Biochim Biophys Acta 1265(2-3):224-227. doi:10.1016/0167-4889(95)00002-a
15. Hanks SK, Hunter T (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9(8):576-596
16. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ (1995) Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267(5198):682-685
17. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 16(3):1247-1255
18. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ (2003) Mechanism of p38 MAP kinase activation in vivo. Genes Dev 17(16):1969-1978. doi:10.1101/gad.1107303 (Pubitemid 36999324)
19. Kumar S, Jiang MS, Adams JL, Lee JC (1999) Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 263(3):825-831. doi:10.1006/bbrc. 1999.1454 (Pubitemid 29490712)
20. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL (2000) Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47(2-3):185-201. doi:10.1016/s0162-3109 (00)00206-x (Pubitemid 30394538)
21. Yada M, Shimamoto A, Hampton CR, Chong AJ, Takayama H, Rothnie CL, Spring DJ, Shimpo H, Yada I, Pohlman TH, Verrier ED (2004) FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg 128(4):588-594. doi:10.1016/j.jtcvs.2004.02.007 (Pubitemid 39278393)
22. Cheung PC, Campbell DG, Nebreda AR, Cohen P (2003) Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J 22(21):5793-5805. doi:10.1093/emboj/cdg552 (Pubitemid 37408818)
23. Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J (2002) MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 295(5558):1291-1294. doi:10.1126/science.1067289 (Pubitemid 34157620)
24. Kumphune S, Bassi R, Jacquet S, Sicard P, Clark JE, Verma S, Avkiran M, O'Keefe SJ, Marber MS (2010) A chemical genetic approach reveals that p38alpha MAPK activation by diphosphorylation aggravates myocardial infarction and is prevented by the direct binding of SB203580. J Biol Chem 285(5):2968-2975. doi:10.1074/jbc.M109.079228
25. Ono K, Han J (2000) The p38 signal transduction pathway: activation and function. Cell Signal 12(1):1-13 (Pubitemid 30017963)
26. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J (1996) Characterization of the structure and function of a new mitogenactivated protein kinase (p38beta). J Biol Chem 271(30):17920-17926 (Pubitemid 26250772)
27. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M (1998) Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 5(6):321-328 (Pubitemid 28309985)
28. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR (1997) Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 235(3):533-538. doi:10.1006/bbrc.1997.6849 (Pubitemid 27326515)
29. See F, Kompa A, Krum H (2004) p38 MAP kinase as a therapeutic target in cardiovascular disease. Drug Discovery Today 1(2):149-154. doi:10.1016/j.ddstr. 2004.08.024 (Pubitemid 40197621)
30. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, Lee JC (1997) Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272(18):12116-12121 (Pubitemid 27202792)
31. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF, Molkentin JD (2004) Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279 (15):15524-15530. doi:10.1074/jbc.M313717200 (Pubitemid 38618953)
32. Kaiser RA, Lyons JM, Duffy JY, Wagner CJ, McLean KM, O'Neill TP, Pearl JM, Molkentin JD (2005) Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 289(6): H2747-H2751. doi:10.1152/ajpheart.01280.2004 (Pubitemid 41698592)
33. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H (2004) p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44(8):1679-1689. doi:10.1016/j.jacc.2004.07.038 (Pubitemid 39369804)
34. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ, Sugden PH (1996) Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79(2):162-173 (Pubitemid 26255867)
35. Saurin AT, Martin JL, Heads RJ, Foley C, Mockridge JW, Wright MJ, Wang Y, Marber MS (2000) The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J 14(14):2237-2246. doi:10.1096/fj.990671com
36. Martin JL, Avkiran M, Quinlan RA, Cohen P, Marber MS (2001) Antiischemic effects of SB203580 are mediated through the inhibition of p38alpha mitogen-activated protein kinase: Evidence from ectopic expression of an inhibition-resistant kinase. Circ Res 89(9):750-752 (Pubitemid 34633844)
37. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR (1998) Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273(4):2161-2168 (Pubitemid 28069266)
38. Gysembergh A, Simkhovich BZ, Kloner RA, Przyklenk K (2001) p38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart. J Mol Cell Cardiol 33(4):681-690. doi:10.1006/jmcc.2000.1331 (Pubitemid 32538981)
39. House SL, Branch K, Newman G, Doetschman T, Schultz Jel J (2005) Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade. Am J Physiol Heart Circ Physiol 289(5):H2167-H2175. doi:10.1152/ajpheart.00392.2005 (Pubitemid 41507370)
40. Khan M, Varadharaj S, Ganesan LP, Shobha JC, Naidu MU, Parinandi NL, Tridandapani S, Kutala VK, Kuppusamy P (2006) C-phycocyanin protects against ischemia-reperfusion injury of heart through involvement of p38 MAPK and ERK signaling. Am J Physiol Heart Circ Physiol 290(5):H2136-H2145. doi:10.1152/ajpheart.01072.2005
41. Schneider S, Chen W, Hou J, Steenbergen C, Murphy E (2001) Inhibition of p38 MAPK alpha/beta reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol Heart Circ Physiol 280(2):H499-H508
42. Sumida T, Otani H, Kyoi S, Okada T, Fujiwara H, Nakao Y, Kido M, Imamura H (2005) Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580. Am J Physiol Heart Circ Physiol 288(6): H2726-H2734. doi:10.1152/ajpheart.01183.2004 (Pubitemid 40720651)
43. Tanno M, Bassi R, Gorog DA, Saurin AT, Jiang J, Heads RJ, Martin JL, Davis RJ, Flavell RA, Marber MS (2003) Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ Res 93(3):254-261. doi:10.1161/01. res.0000083490.43943.85 (Pubitemid 36993237)
44. Aleshin A, Sawa Y, Ono M, Funatsu T, Miyagawa S, Matsuda H (2004) Myocardial protective effect of FR167653; a novel cytokine inhibitor in ischemic-reperfused rat heart. Eur J Cardiothorac Surg 26(5):974-980. doi:10.1016/j.ejcts.2004.06.021 (Pubitemid 39433882)
45. Clanachan AS, Jaswal JS, Gandhi M, Bottorff DA, Coughlin J, Finegan BA, Stone JC (2003) Effects of inhibition of myocardial extracellular-responsive kinase and P38 mitogen-activated protein kinase on mechanical function of rat hearts after prolonged hypothermic ischemia. Transplantation 75(2):173-180. doi:10.1097/01. tp.0000040429.40245.3a (Pubitemid 36139667)
46. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, Wang C, Lee JC, Feuerstein GZ, Yue TL (1999) Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99(13):1685-1691 (Pubitemid 29162480)
47. Meldrum DR, Dinarello CA, Cleveland JC Jr, Cain BS, Shames BD, Meng X, Harken AH (1998) Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery 124(2):291-296, discussion 297
48. Wang M, Tsai BM, Turrentine MW, Mahomed Y, Brown JW, Meldrum DR (2005) p38 mitogen activated protein kinase mediates both death signaling and functional depression in the heart. Ann Thorac Surg 80(6):2235-2241. doi:10.1016/j. athoracsur.2005.05.070 (Pubitemid 41718063)
49. Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM (2000) The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res Cardiol 95(6):472-478 (Pubitemid 32013987)
50. Nagarkatti DS, Sha'afi RI (1998) Role of p38 MAP kinase in myocardial stress. J Mol Cell Cardiol 30(8):1651-1664 (Pubitemid 28418654)
51. Nakano A, Cohen MV, Critz S, Downey JM (2000) SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol 95 (6):466-471 (Pubitemid 32013986)
52. Sanada S, Kitakaze M, Papst PJ, Hatanaka K, Asanuma H, Aki T, Shinozaki Y, Ogita H, Node K, Takashima S, Asakura M, Yamada J, Fukushima T, Ogai A, Kuzuya T, Mori H, Terada N, Yoshida K, Hori M (2001) Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circ Res 88(2):175-180 (Pubitemid 32147305)
53. Weinbrenner C, Liu GS, Cohen MV, Downey JM (1997) Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 29(9):2383-2391. doi:10.1006/jmcc.1997.0473 (Pubitemid 27404431)
54. Brady NR, Hamacher-Brady A, Gottlieb RA (2006) Proapoptotic BCL-2 family members and mitochondrial dysfunction during ischemia/reperfusion injury, a study employing cardiac HL-1 cells and GFP biosensors. Biochim Biophys Acta 1757(5-6):667-678. doi:10.1016/j.bbabio.2006.04.011 (Pubitemid 43993858)
55. Colston JT, de la Rosa SD, Freeman GL (2004) Impact of brief oxidant stress on primary adult cardiac fibroblasts. Biochem Biophys Res Commun 316(1):256-262. doi:10.1016/j. bbrc.2004.02.042 (Pubitemid 38299154)
56. Cooper M, Ytrehus K (2004) Cell survival signalling in heart derived myofibroblasts induced by preconditioning and bradykinin: the role of p38 MAP kinase. Mol Cell Biochem 259(1-2):83-90 (Pubitemid 38519219)
57. Kim JK, Pedram A, Razandi M, Levin ER (2006) Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. J Biol Chem 281(10):6760-6767. doi:10.1074/jbc.M511024200 (Pubitemid 43847612)
58. Mackay K, Mochly-Rosen D (1999) An inhibitor of p38 mitogenactivated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem 274(10):6272-6279 (Pubitemid 29111038)
59. Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA, Lochner A (2001) Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J Mol Cell Cardiol 33(4):769-778. doi:10.1006/jmcc.2001.1347 (Pubitemid 32538989)
60. Okada T, Otani H, Wu Y, Kyoi S, Enoki C, Fujiwara H, Sumida T, Hattori R, Imamura H (2005) Role of F-actin organization in p38 MAP kinase-mediated apoptosis and necrosis in neonatal rat cardiomyocytes subjected to simulated ischemia and reoxygenation. Am J Physiol Heart Circ Physiol 289(6):H2310-H2318. doi:10.1152/ajpheart.00462.2005 (Pubitemid 41698537)
61. Rakhit RD, Kabir AN, Mockridge JW, Saurin A, Marber MS (2001) Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemiareoxygenation injury. Biochem Biophys Res Commun 286 (5):995-1002. doi:10.1006/bbrc.2001.5477 (Pubitemid 32924870)
62. Sharov VG, Todor A, Suzuki G, Morita H, Tanhehco EJ, Sabbah HN (2003) Hypoxia, angiotensin-II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D1. Eur J Heart Fail 5 (2):121-129 (Pubitemid 36383618)
63. Sucher R, Gehwolf P, Kaier T, Hermann M, Maglione M, Oberhuber R, Ratschiller T, Kuznetsov AV, Bosch F, Kozlov AV, Ashraf MI, Schneeberger S, Brandacher G, Ollinger R, Margreiter R, Troppmair J (2009) Intracellular signaling pathways control mitochondrial events associated with the development of ischemia/reperfusion-associated damage. Transpl Int 22(9):922-930. doi:10.1111/j.1432-2277.2009.00883.x
64. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G (2001) Signal transduction of ischemic preconditioning. Cardiovasc Res 52(2):181-198 (Pubitemid 33000395)
65. Gorog DA, Tanno M, Cao X, Bellahcene M, Bassi R, Kabir AM, Dighe K, Quinlan RA, Marber MS (2004) Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia. Cardiovasc Res 61(1):123-131 (Pubitemid 38056688)
66. Kabir AM, Cao X, Gorog DA, Tanno M, Bassi R, Bellahcene M, Quinlan RA, Davis RJ, Flavell RA, Shattock MJ, Marber MS (2005) Antimycin A induced cardioprotection is dependent on pre-ischemic p38-MAPK activation but independent of MKK3. J Mol Cell Cardiol 39(4):709-717. doi:10.1016/j. yjmcc.2005.07.012 (Pubitemid 41331059)
67. Moolman JA, Hartley S, Van Wyk J, Marais E, Lochner A (2006) Inhibition of myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is dependent on p38 MAPK. Cardiovasc Drugs Ther 20(1):13-25. doi:10.1007/s10557- 006-6257-7
68. Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL (2002) p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 53(2):414-422 (Pubitemid 34117692)
69. Zhang GM, Su SP, Wang Y, Li TD, Li XY, Tan H, Zhang DW, Zhang H, Liu LF (2010) Effect of ischemic postconditioning on activation of p38 mitogen activated protein kinase and cardiocyte apoptosis in rats. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 32 (5):526-532. doi:10.3881/j.issn.1000-503X.2010.05.012
70. Kompa AR, See F, Lewis DA, Adrahtas A, Cantwell DM, Wang BH, Krum H (2008) Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J Pharmacol Exp Ther 325(3):741-750. doi:10.1124/jpet.107.133546 (Pubitemid 351724310)
71. Li M, Georgakopoulos D, Lu G, Hester L, Kass DA, Hasday J, Wang Y (2005) p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 111(19):2494-2502. doi:10.1161/01. cir.0000165117.71483.0c (Pubitemid 40696138)
72. Liu YH, Wang D, Rhaleb NE, Yang XP, Xu J, Sankey SS, Rudolph AE, Carretero OA (2005) Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. J Card Fail 11(1):74-81 (Pubitemid 40215318)
73. Sy JC, Seshadri G, Yang SC, Brown M, Oh T, Dikalov S, Murthy N, Davis ME (2008) Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction. Nat Mater 7 (11):863-868. doi:10.1038/nmat2299
74. Yin H, Zhang J, Lin H, Wang R, Qiao Y, Wang B, Liu F (2008) p38 mitogen-activated protein kinase inhibition decreases TNFalpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia. Inflammation 31(2):65-73. doi:10.1007/s10753-007-9050-2 (Pubitemid 351388889)
75. Schulz R, Belosjorow S, Gres P, Jansen J, Michel MC, Heusch G (2002) p38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovasc Res 55(3):690-700 (Pubitemid 34874961)
76. Barancik M, Htun P, Strohm C, Kilian S, Schaper W (2000) Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol 35(3):474-483 (Pubitemid 30127197)
77. Engel FB, Hsieh PC, Lee RT, Keating MT (2006) FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci USA 103(42):15546-15551. doi:10.1073/pnas.0607382103 (Pubitemid 44625629)
78. Di Diego JM, Antzelevitch C (2011) Ischemic ventricular arrhythmias: Experimental models and their clinical relevance. Heart Rhythm 8:1963-1968. doi:10.1016/j.hrthm.2011.06.036
79. Chen Z, Luo H, Zhuang M, Cai L, Su C, Lei Y, Zou J (2011) Effects of ischemic preconditioning on ischemia/reperfusion-induced arrhythmias by upregulatation of connexin 43 expression. J Cardiothorac Surg 6:80. doi:10.1186/1749-8090-6-80
80. Marber MS, Molkentin JD, Force T (2010) Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point. Drug Discov Today Dis Mech 7(2):e123-e127. doi:10.1016/j.ddmec.2010.07.006
81. Sweeney SE (2009) The as-yet unfulfilled promise of p38 MAPK inhibitors. Nat Rev Rheumatol 5(9):475-477. doi:10.1038/nrrheum.2009.171
82. U.S. National Institutes of Health (2011) A study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without ST-segment elevation (Solstice). Available at: http://clinicaltrials. gov/ct2/show/study/NCT00910962?term0GW856553&rank06. Accessed 26 Sept 2011
83. Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B, Ohlstein EH (2000) Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 86(6):692-699 (Pubitemid 30208438)
84. Mackay K, Mochly-Rosen D (2000) Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia. J Mol Cell Cardiol 32 (8):1585-1588. doi:10.1006/jmcc.2000.1194
85. Sicard P, Clark JE, Jacquet S, Mohammadi S, Arthur JS, O'Keefe SJ, Marber MS (2010) The activation of p38 alpha, and not p38 beta, mitogen-activated protein kinase is required for ischemic preconditioning. J Mol Cell Cardiol 48(6):1324-1328. doi:10.1016/j.yjmcc.2010.02.013
86. Schwertz H, Carter JM, Abdudureheman M, Russ M, Buerke U, Schlitt A, Muller-Werdan U, Prondzinsky R, Werdan K, Buerke M (2007) Myocardial ischemia/reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor. Proteomics 7(24):4579-4588. doi:10.1002/pmic.200700734
87. Koike N, Takeyoshi I, Ohki S, Tokumine M, Matsumoto K, Morishita Y (2004) Effects of adding P38 mitogen-activated protein-kinase inhibitor to celsior solution in canine heart transplantation from non-heart-beating donors. Transplantation 77 (2):286-292. doi:10.1097/01.TP.0000101039.12835.A4 (Pubitemid 38155760)